Article Text

Download PDFPDF

Alterations in p53 predict response to preoperative high dose chemotherapy in patients with gastric cancer
Free
  1. F Bataille1,
  2. P Rümmele1,
  3. W Dietmaier1,
  4. D Gaag1,
  5. F Klebl2,
  6. A Reichle3,
  7. P Wild1,
  8. F Hofstädter1,
  9. A Hartmann1
  1. 1Department of Pathology, University of Regensburg, 93042 Regensburg, Germany
  2. 2Department of Internal Medicine I, University of Regensburg
  3. 3Department of Hematology and Oncology, University of Regensburg
  1. Correspondence to:
 Dr F Bataille, Department of Pathology, University of Regensburg, 93042 Regensburg, Germany;
 frauke.bataille{at}klinik.uni-regensburg.de

Abstract

Aims: To evaluate the usefulness of molecular markers in predicting histopathological and clinical response to preoperative high dose chemotherapy (HDCT) and survival of patients with advanced gastric cancer.

Methods: In a phase II trial, 25 patients with metastatic gastric cancer received preoperative tandem HDCT consisting of etoposide, cisplatin, and mitomycin, followed by autologous bone marrow transplantation to achieve surgical resectability. Samples before and after treatment, from normal and tumour tissue, were characterised histopathologically, and both p53 and BAX expression was analysed by immunohistochemistry. Pretreatment formalin fixed, paraffin wax embedded samples from normal and tumour tissue were microdissected, and the extracted DNA was preamplified using improved primer extension preamplification polymerase chain reaction. Detection of microsatellite instability (MSI) or loss of heterozygosity (LOH) was performed using markers for p53, BAX, BAT25, BAT26, D2S123, D17S250, and APC. Exons 5–9 of the p53 gene were sequenced directly on ABI 373.

Results: Four parameters were significantly associated with response to chemotherapy and prolonged overall survival: positive p53 immunostaining, positive p53 mutation status before chemotherapy, strong histological regression induced by preoperative HDCT, and surgical treatment. Patients’s sex or age, tumour location or stage, lymph node status, Lauren classification, MSI, or LOH did not influence duration of survival significantly in this high risk population.

Conclusion: Positive p53 immunostaining and p53 mutation status in pretreatment tumour biopsies might be useful molecular predictors of response and prognosis in patients with advanced gastric cancer treated by preoperative HDCT.

  • gastric cancer
  • preoperative high dose chemotherapy
  • molecular parameters
  • histological regression
  • p53
  • ABMT, autologous bone marrow transplantation
  • HDCT, high dose chemotherapy
  • LOH, loss of heterozygosity
  • MSI, microsatellite instability
  • MSI-H, microsatellite unstable
  • PCR, polymerase chain reaction
View Full Text

Statistics from Altmetric.com

Footnotes

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.